Biospecimen Availability Overview
The table below provides an overview of what types of biospecimens are available in each cohort study.
| Cohort | Population | Research Intent | DNA | RNA | CSF | Whole Blood | Plasma | Serum | Urine | Peripheral Mononuclear Blood Cells |
|---|---|---|---|---|---|---|---|---|---|---|
| NINDS Parkinson's disease Biomarkers Program (PDBP) | Early to advance PD and controls | |||||||||
| 24-Hour Biofluid Sampling | Early to moderate PD and controls | Biomarker discovery | ||||||||
| BioFind | Moderate to advanced PD and controls | Biomarker discovery | ||||||||
| DATATOP | Early, unmedicated PD | Biomark discovery and validation | ||||||||
| FS-ZONE | 217 individuals with early PD | Phase II placebo-controlled study of the safety and effect of two dosages of oral pioglitazone | ||||||||
| Harvard Biomarker Study | >600 early-stage, medicated and unmedicated cases with PD, >600 individuals with congnitive impairment, and >700 controls | Discovery and validation of cross-sectional and longitudinal biomarkers for PD and AD | ||||||||
| LRRK2 Cohort | Biomarker discovery | Biomarker discovery | ||||||||
| STEADY-III | 336 subjects with early idiopathic PD not requiring dopaminergic therapy | Pharmacogenetics/pharmacodynamics | ||||||||
| SURE-PD3 | 298 Individuals with early Parkinson's Disease | Pharmacogenetics/pharmacodynamics | ||||||||
| SURE-PD2 | 75 individuals with early Parkinson's Disease | Pharmacogenetics/pharmacodynamics | ||||||||
| Nilo-PD | 76 individuals with moderate to advanced PD | Assay development, biomarker discovery, pharmacogenetics/pharmacodynamics, biomarker replication & validation | ||||||||
| CERE-120 | 148 individuals with PD | Assay development, biomarker discovery, pharmacogenetics/pharmacodynamics | ||||||||
| AVE-8112 | 13 individuals with PD | Assay development, biomarker discovery, pharmacogenetics/pharmacodynamics |